Serum Crosslaps? (CTX-I) ELISA 品牌Immunoassay Systems | IDS

點(diǎn)擊看大圖

如果您對(duì)該產(chǎn)品感興趣的話,可以

產(chǎn)品名稱: Serum Crosslaps? (CTX-I) ELISA 品牌Immunoassay Systems | IDS

產(chǎn)品型號(hào): AC-02F1

產(chǎn)品展商: 其他品牌

產(chǎn)品文檔: 無(wú)相關(guān)文檔

簡(jiǎn)單介紹

品名：Serum Crosslaps? (CTX-I) ELISA 貨號(hào)：AC-02F1

Serum Crosslaps? (CTX-I) ELISA 品牌Immunoassay Systems | IDS 的詳細(xì)介紹

Code:	AC-02F1
Certification:	CE Marked FDA Cleared
Clinical Area:	Bone Metabolism
Type:	Manual
Format:	ELISA
RUO/IVD:	IVD
Number of Tests:	96 (40 samples in duplicate)
Sample Type:	Serum or Plasma
Sample Volume:	50 μL
Assay Range:	0-3.380 ng/mL

Unique Features

Management of Postmenopausal Osteoporosis
Prediction of long-term skeletal response to anti-resorptive therapies, e.g. HRT, bisphosphonates
Increase in patient motivation and compliance
Assessment of Bone Resorption in Patients
With metabolic bone disease, e.g. hyperparathyroidism, Paget′s disease, osteodystrophy
Receiving prolonged glucocorticoid therapy
A reference marker for osteoporosis management as indicated by IOF, IFCC and NBHA
Easy to perform – one step incubation
Excellent correlation with automated methods
A complete assay panel supporting bone disease management

Product Description

The Serum CrossLaps® (CTX-I) ELISA is an enzyme immunological test for the quantification of degradation products of C-terminal telopeptides of Type I collagen in human serum and plasma.

The Serum CrossLaps® (CTX-I) ELISA assay is intended for in-vitro diagnostic use as an indication of human bone resorption and may be used as an aid in:

1. Monitoring bone resorption changes of:

a) Anti-resorptive therapies in postmenopausal women1, 2:

Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
Bisphosphonate therapies

b) Anti-resorptive therapies in individuals diagnosed with osteopaenia:

Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
Bisphosphonate therapies

2. Predicting skeletal response (Bone Mineral Density) in postmenopausal women undergoing
anti-resorptive therapies:

a) Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs

b) Bisphosphonate therapies

Type I collagen accounts for more than 90% of the organic matrix of bone and is synthesised primarily in bone. During renewal of the skeleton, Type I collagen is degraded and small peptide fragments are excreted into the bloodstream. Serum levels of these degradation products, such as CTX-I, are highly correlated with the bone turnover rate and allow an assessment of the rate of bone resorption.

The Serum CrossLaps® (CTX-I) ELISA is based on two highly specific monoclonal antibodies against the amino acid sequence of EKAHD-?-GGR, where the aspartic acid residue (D) is ?-isomerised. In order to obtain a specific signal in the Serum CrossLaps® (CTX-I) ELISA, two chains of EKAHD-?-GGR must be cross-linked.

As of late 2010, IOF and IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) recommend the serum CTX-I as a bone resorption marker for use in observational and intervention studies, in order to compare the performance of alternatives and to widen international experience of the application of bone markers to clinical medicine3.

Publications

McClung MR et al., Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013 Jan;24(1):227-35

Stoch SA et al., Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics–results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol. 2013 May;75(5):1240-54

Vasikaran SD et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2010; 22(2):391-420.